TITLE

Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application

AUTHOR(S)
Höhn, Fabian; Mirshahi, Alireza
PUB. DATE
October 2010
SOURCE
Graefe's Archive of Clinical & Experimental Ophthalmology;Oct2010, Vol. 248 Issue 10, p1371
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: To examine the influence of different intravitreous injection techniques on the short-term intraocular pressure (IOP) in patients with exudative age-related macular degeneration (AMD) receiving 0.05 ml ranibizumab (Lucentis®) in the supine position. Methods: Forty-five eyes (45 patients, 16 male, 29 female, mean age: 78 years) received intravitreal ranibizumab injections for treatment of exudative AMD (0.05 ml = 0.5 mg). A total of 31 patients received a standard straight scleral incision, and 14 were injected using the tunneled sclera technique. IOP was measured by Schiøtz tonometry immediately pre-and postoperatively, and the amount of subconjunctival reflux was documented using a semi-quantitative scale. Twenty-three eyes were phakic, and the remaining 22 were pseudophakic. No history of glaucoma was present. The Wilcoxon matched-pairs test was used for comparisons. Results: The mean preoperative IOP was 22.4 ± 5.5 mmHg in the supine position. Immediately after the injection, the IOP increased to 47.9 ± 15.1 (range 23–82). The mean difference between preoperative IOP and immediately after the injection was 25.5 ± 13.6 mmHg. The mean IOP increase in eyes receiving a standard straight scleral incision was 21.9 ± 14.2 mmHg (median 22.3) versus 33.5 ± 7.2 mmHg (median 34.7) in the tunneled scleral incision group ( p = 0.001). Conclusions: IOP increased significantly in a considerable number of patients after receiving 0.05-ml intravitreal ranibizumab injections. This increase was dependent on the intravitreal injection technique and was significantly higher if a tunneled scleral injection was performed.
ACCESSION #
52995821

 

Related Articles

  • Profilaktik Antiglokomatöz Tedavinin 0.1 ml Ä°ntravitreal Bevacizumab Enjeksiyonu Sonrası Göz İçi Basıncına Kısa Dönem Etkisi. AKARSU, Özge Pınar; GÜVEN, Dilek; ATILGAN, Cemile ÜÇGÜL; UZUN, Saniye ÜKE // Retina-Vitreus/Journal of Retina-Vitreous;Mar2013, Vol. 21 Issue 1, p48 

    Purpose: To evaluate the efficacy of timolol, timolol-dorzolamide and timolol-brimonidine drops used prophylactically before IVB on the prevention of IOP rise. Materials and Methods: Sixty four non-glaucomatous patients received 2.5 mg IVB for choroidal neovascularisation (NV) not secondary to...

  • Proteomics of Vitreous Humor of Patients with Exudative Age-Related Macular Degeneration. Koss, Michael Janusz; Hoffmann, Janosch; Nguyen, Nauke; Pfister, Marcel; Mischak, Harald; Mullen, William; Husi, Holger; Rejdak, Robert; Koch, Frank; Jankowski, Joachim; Krueger, Katharina; Bertelmann, Thomas; Klein, Julie; Schanstra, Joost P.; Siwy, Justyna // PLoS ONE;May2014, Vol. 9 Issue 5, p1 

    Background: There is absence of specific biomarkers and an incomplete understanding of the pathophysiology of exudative age-related macular degeneration (AMD). Methods and Findings: Eighty-eight vitreous samples (73 from patients with treatment naïve AMD and 15 control samples from patients...

  • A Future Tx for VMT? Shechtman, Diana L.; Karpecki, Paul M. // Review of Optometry;6/15/2011, Vol. 148 Issue 6, p110 

    The article discusses the potential use of pharmacological vitreolyisis to treat patients with vitreomacular traction (VMT) syndrome. Studies reveal that the use of pharmacological vitreolyisis is a more efficient and safer option to treat VMT patients. Furthermore, the said alternative...

  • SalutarisMD Presents Dosimetry Data for Promising Device to Treat Leading Cause of Blindness at AAPM Annual Meeting.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article offers information on the American Association of Physicists in Medicine Annual Meeting which featured a presentation on dosimetry data for episcleral brachytherapy device by professor Russell J. Hamilton. It further informs that the Salutaris Medical Devices Inc. has developed the...

  • Injection Shows Modest Success Against AMD.  // Review of Optometry;12/15/2003, Vol. 140 Issue 12, p6 

    Reports on the efficacy of pegaptanib sodium, an anti-VEGF drug injected into the eye, in blocking neovascularization in the wet form of age-related macular degeneration (AMD). Correlation of the presence of vascular endothelial growth factor (VEGF) in AMD with choroidal neovascularization;...

  • Researchers look to fill need for longer duration medications, delivery systems. Morgan, Daniel R.; Nale, Patricia; Stiglich, Joan-Marie // Primary Care Optometry News;Mar2014, Vol. 19 Issue 3, p16 

    The article reports on the use of intravitreal injections or sustained release solid implant intravitreal devices in treating patients with age-related macular degeneration discussed by Dr. William F. Mieler, professor and vice-chairman of the Department of Ophthalmology & Visual Sciences at the...

  • New AMD treatment licensed. McCormick, Emily // Optometry Today;12/14/2012, Vol. 52 Issue 24, p6 

    The article reports that Bayer's Eylea injection treatment for wet age-related macular degeneration (AMD) has been approved for use in Europe and will be subjected for appraisal of the National Institute of Health and Clinical Excellence (NICE).

  • WHAT EVERY ASSISTANT NEEDS TO KNOW ABOUT INTRAVITREAL INJECTION. Tafoya, Mark E. // Optometry Times;Sep2013 Supplement iTech, p11 

    The author provides an understanding to doctors' assistant about the use of intravitreal injection in treating diseases such as wet macular degeneration, macular edema and diabetic macular edema. He mentions several intraveal injections that have been introduced in the market. He shares tips on...

  • Intravitreal injection of ranibizumab for foveal-macular pattern dystrophy: case report. DE MELLO VENTURA, ALEXANDRE AUGUSTO CABRAL; GRANT, LORNA WINIFRED; DADGOSTAR, HAJIR; LEWIS, HILEL // Arquivos Brasileiros de Oftalmologia;2011, Vol. 74 Issue 4, p289 

    In the recent years, anti-angiogenic medications have successfully treated other diseases associated with choroidal neovascularization. The anti-angiogenic therapy alone or combined with LASER and/or steroids has been effective in controlling ocular neovascularization, not only restricted to the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics